Clinical Trial Update: Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase III trial of VDJ001 for moderate-to-severe active rheumatoid arthritis is currently enrolling by invitation, evaluating an anti–IL-6 receptor therapy. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• VDJ001

Snippet

Sponsor: Beijing VDJBio Co., LTD. | Conditions: Rheumatoid Arthritis (RA), Anti IL-6R | Phase 3 | Status: ENROLLING_BY_INVITATION